About
Alan S. Cuthbertson is one of Europe's most experienced radiopharmaceutical scientists — a consultant, advisor, and scientist with more than 25 years at the forefront of radiopharmaceutical sciences.
After completing his PhD in Organic Chemistry at the University of Edinburgh, Alan built his career across the leading institutions shaping the field — including GE Healthcare, Algeta, and Bayer — working across radiopharmaceutical science in molecular imaging and targeted radiotherapy.
At Bayer AS in Oslo, he served as Head of R&D for targeted alpha radiotherapy, building the chelation chemistry, conjugation platform, and preclinical evaluation framework that underpins Bayer's clinical-stage targeted alpha-particle therapy pipeline. His work spans the full arc of radiopharmaceutical discovery: from novel octadentate HOPO chelator synthesis to biodistribution, dosimetry, and IND-enabling packages across prostate, breast, and mesothelioma indications.
Now operating independently, Cuthbertson Radiopharm Consulting works with pharmaceutical and biotech organisations, as well as academic institutes, seeking rigorous scientific expertise at the intersection of chemistry, oncology, and nuclear medicine — with a particular focus on advancing access to targeted radiotherapeutics across the Scandinavian market.
Alan S. Cuthbertson
PhD Organic Chemistry, University of Edinburgh